Sold for pen­nies, Unum gets one last shot at re­demp­tion

Unum Ther­a­peu­tics’ cell ther­a­py tech is get­ting one last lease on life af­ter a Czech biotech was able to pick up the core of a once-bal­ly­hooed com­pa­ny for the cost of spare parts.

For $8.1 mil­lion up­front and just $3.4 mil­lion in mile­stones, Prague-based cell ther­a­py start­up So­tio bought out the pre­clin­i­cal “BOXR” CAR-T plat­form that Unum said they would turn to in March, af­ter a third round of safe­ty is­sues in as many years proved the fi­nal straw for their lead pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER